Tag: clinical study
Aimmune Therapeutics Presents New AR101 Data Including Demonstrated Reduction in Accidental...
AR101-Treated Patients Who Completed PALISADE Had 95% Increased Probability of Tolerating Any Dose of Peanut Protein in Exit Challenge Compared to Placebo.
Phase I Trial for New Peanut Allergy Immunotherapy Results in No...
Research details phase one study of peptide-based immunotherapy, which is designed to remove risks of acute reactions during treatment.
Aimmune to Begin Phase 2 Trials of Egg Allergy OIT Candidate
AR201 for Egg Allergy Phase 2 Initiation Planned for 2019.
Can Fecal Transplant Cure Peanut Allergy? Phase I Trial Underway
Can transplanting the microbiota of a healthy person to that of an allergic individual prevent allergic reactions?
Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...
Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...
Study scheduled to commence next week.
Viaskin Peanut Completes Phase III Part A Study of Toddlers With...
Part B expected to commence in 2018Q4 with Viaskin Peanut 250 µg.
Enrollment Complete for Phase 2b Probiotic Oral Immunotherapy Treatment Candidate
Study to provide evidence of longer lasting tolerance to peanut in a larger number of patients.
Study: Dupilumab Showed Positive Phase 3 Results in Adolescents with Inadequately...
"[dupilumab] blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation."
Study: IgG Antibodies Activate Blood Platelets and Contribute to the Severity...
"This work demonstrates the potential of exploring therapeutic interventions that target platelets as means of limiting the severity of anaphylactic shock."
